Chest Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deenstra, H.
Right arrow Articles by Van Ditmars, M. J.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Deenstra, H.
Right arrow Articles by Van Ditmars, M. J.
(Chest. 1968;53:57-61.)
© 1968 American College of Chest Physicians

Sarcoidosis

H. Deenstra M.D., F.C.C.P.1 and M. J. Van Ditmars M.D.1

1 Utrecht, The Netherlands

The diagnosis of sarcoidosis can nearly always be established by an assessment of the clinical picture in combination with the histologic features of a biopsy specimen.

Knowledge of the natural course of the disease is required in determining the indication for corticosteroid therapy.

The majority of patients with sarcoidosis of the lungs require no treatment. If the need to prevent the occurrence or progression of fibrosis calls for therapy, then the latter must adhere to a strictly formulated regimen.

Two therapeutic regimens are discussed. The general recommendation favors regimen 1, which calls for corticosteroid medication during a five-year period. Regimen 2 is used whenever the standard regimen is considered too rigorous, e.g. in the treatment of patients over age 45 or if the indication for therapy is questionable.

Careful management of patients with sarcoidosis nearly always succeeds in preventing the occurrence or progression of fibrosis. An insufficiently high dosage or premature discontinuation of treatment often leads to recurrence, prolongation of therapy and the occurrence of irreversible fibrosis.

The number of patients unnecessarily treated with corticosteroids can be limited by a careful study of the natural course of the disease. This requires the use of a classification in stages with the aid of an atlas.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1968 by the American College of Chest Physicians.